Pharmaceutical - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

151 to 175 of 400 results

Novo Nordisk’s profits rise 15% with further growth expected

Novo Nordisk’s profits rise 15% with further growth expected

30-01-2014

Danish insulin giant Novo Nordisk has announced a 15% growth in profit in the firm’s 2013 financial…

DenmarkDiabetesFinancialNovo NordiskPharmaceuticalTresibaVictoza

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

27-01-2014

A unique collaboration between leading London hospitals and Danish insulin giant Novo Nordisk (NOV: N)…

DiabetesHealthcareNovo NordiskPharmaceuticalUK

Pharma appeals to Ukraine Health Ministry on insulin supply problems

Pharma appeals to Ukraine Health Ministry on insulin supply problems

27-01-2014

The Association of Pharmaceutical Research and Development and the American Chamber of Commerce in Ukraine…

DiabetesEastern EuropeHealthcarePharmaceuticalPricingUkraine

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

24-01-2014

Among a batch of positive opinions issued today by the European Medicines Agency’ s Committee for Medicinal…

DiabetesEperzanGlaxoSmithKlinePharmaceuticalRegulation

AstraZeneca’s fixed-dose diabetes drug Xigduo approved in Europe

AstraZeneca’s fixed-dose diabetes drug Xigduo approved in Europe

22-01-2014

The European Commission has approved Anglo-Swedish drug major AstraZeneca and soon to be ex-partner USA-based…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesPharmaceuticalRegulationXigduo

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat

20-01-2014

Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

“Differing views” see Zealand and Boehringer change collaboration compound

“Differing views” see Zealand and Boehringer change collaboration compound

20-01-2014

Zealand Pharma and Boehringer Ingelheim will change the development program involving novel glucagon/GLP-1…

Boehringer IngelheimDenmarkDiabetesGermanyPharmaceuticalResearchZealand Pharma

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

16-01-2014

Denmark’s Zealand Pharma says it has achieved a milestone under its collaboration with French drug…

DiabetesFinancialLixiLanLyxumiaPharmaceuticalResearchSanofiZealand Pharma

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

09-01-2014

Reversing a previous 2012 negative decision, the US Food and Drug Administration yesterday approved Anglo-Swedish…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesFarxigaNorth AmericaPharmaceuticalRegulationUSA

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

19-12-2013

Confirming recent runors, Anglo-Swedish drug major AstraZeneca revealed this morning that it will acquire…

AstraZenecaBristol-Myers SquibbDiabetesExenatide InjectionMergers & AcquisitionsOnglyzaPharmaceutical

US FDA calls for more data on Janssen’s fixed dose diabetes drug

US FDA calls for more data on Janssen’s fixed dose diabetes drug

16-12-2013

US health care giant Johnson & Johnson has received a complete response letter from the Food and Drug…

canagliflozinDiabetesJanssenJohnson & JohnsonmetforminNorth AmericaPharmaceuticalRegulation

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

14-12-2013

Drug majors Bristol-Myers Squibb and AstraZeneca have reportedly decided to stop marketing their diabetes…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaMarkets & MarketingPharmaceuticalPricing

Strong FDA advisory panel backing for Bristol-Myers/AstraZeneca’s diabetes drug

Strong FDA advisory panel backing for Bristol-Myers/AstraZeneca’s diabetes drug

13-12-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesForxigaNorth AmericaPharmaceuticalRegulation

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Novo Nordisk accused of delaying information release under Danish STC rules

Novo Nordisk accused of delaying information release under Danish STC rules

10-12-2013

Danish insulin giant Novo Nordisk revealed this morning that the Danish Financial Supervisory Authority…

DenmarkDiabetesEuropeFinancialLegalNovo NordiskPharmaceuticalRyzodegTresiba

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

05-12-2013

Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

03-12-2013

Danish insulin giant Novo Nordisk has presented positive new Phase III data from the investigational…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearch

Sanofi reports positive results for investigational insulin U300

Sanofi reports positive results for investigational insulin U300

03-12-2013

French drug major Sanofi revealed encouraging full results from the EDITION II study, showing that its…

DiabetesPharmaceuticalResearchSanofiU300

Novo Nordisk aims to expand its already leading position in diabetes care

Novo Nordisk aims to expand its already leading position in diabetes care

03-12-2013

Denmark-based global insulin giant Novo Nordisk this morning set out its ambition to further expand its…

DiabetesHematologyliraglutideMetabolicsNovo NordiskOG217SCPharmaceuticalsemaglutideVictoza

Survey aims to discover how early diabetes diagnoses can aid better outcomes

Survey aims to discover how early diabetes diagnoses can aid better outcomes

02-12-2013

A multinational survey of more than 10,000 people with type 2 diabetes has been launched by German family-owned…

Boehringer IngelheimDiabetesEli LillyGlobalPharmaceuticalResearch

151 to 175 of 400 results

Back to top